NCT02243592 2026-03-18
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
National Cancer Institute (NCI)
Active not recruiting
Clinical Trials
202 trialsNCT03030378 2026-03-18
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04317105 2026-03-18
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05554341 2026-03-18
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04958239 2026-03-17
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07474168 2026-03-16
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Zhejiang University
Phase 1 Active not recruiting
NCT04318886 2026-03-13
Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT
University of Alabama at Birmingham
Phase 3 Active not recruiting
NCT02908906 2026-03-12
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT04803604 2026-03-12
CASCADE
University of Alabama at Birmingham
Phase NA Active not recruiting
NCT07468422 2026-03-12
OPTin
China Medical University Hospital
Active not recruiting
NCT00001163 2026-03-11
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT05763797 2026-03-11
Developing a Culturally Relevant Supportive Care Program for Black Patients Dealing With Advanced Cancer
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05993299 2026-03-11
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06864260 2026-03-11
PREEMpT
University of Alabama at Birmingham
Phase NA Active not recruiting
NCT05707910 2026-03-09
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
West China Hospital
Phase 1 Active not recruiting
NCT06549153 2026-03-09
ACT-Together (Acting on Cancer Testing-Together)
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT01428895 2026-03-06
Femoral Bone Metastases
University Health Network, Toronto
Phase NA Active not recruiting
NCT04135794 2026-03-05
MRL1
University Health Network, Toronto
Active not recruiting
NCT05611632 2026-03-05
NHS-Galleri
GRAIL, Inc.
Phase NA Active not recruiting
NCT00832325 2026-03-03
Adolescent and Young Adult Cancer Survivors: Identity Development
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT04913259 2026-03-03
TS-PAC
Institut Bergonié
Phase NA Active not recruiting
NCT04294628 2026-02-27
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06703346 2026-02-25
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT00750841 2026-02-23
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT07427355 2026-02-23
ASANDE
Alliance For Medical Research in Africa
Active not recruiting
NCT05823740 2026-02-20
Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers
UNC Lineberger Comprehensive Cancer Center
Phase NA Active not recruiting
NCT03927885 2026-02-19
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer
M.D. Anderson Cancer Center
Phase 2/3 Active not recruiting
NCT04150900 2026-02-19
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
University of Maryland, Baltimore
Phase 2 Active not recruiting
NCT05396833 2026-02-19
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono
Phase 1 Active not recruiting
NCT07093567 2026-02-18
Opiophobia in Adults With Advanced Cancer
M.D. Anderson Cancer Center
Active not recruiting
NCT04150939 2026-02-17
Cryoablation for the Treatment of Metastatic Cancer
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05117931 2026-02-17
A Study of Amivantamab in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06340906 2026-02-13
Electroacupuncture in Symptom Management After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
University of California, Irvine
Phase NA Active not recruiting
NCT04078295 2026-02-10
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT07396740 2026-02-09
DISTRO
University Hospital, Brest
Active not recruiting
NCT03260023 2026-02-05
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Transgene
Phase 1/2 Active not recruiting
NCT02584933 2026-02-03
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Active not recruiting
NCT04733469 2026-02-02
EMPOWER 3
Tulane University
Phase NA Active not recruiting
NCT06077877 2026-02-02
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT06926972 2026-02-02
NOURISH
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Active not recruiting
NCT03964727 2026-01-30
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
NCT04170153 2026-01-30
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono
Phase 1 Active not recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03436290 2026-01-28
SCOPE
Vanderbilt University Medical Center
Phase NA Active not recruiting
NCT06693128 2026-01-28
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Ruijin Hospital
Phase 2 Active not recruiting
NCT07368192 2026-01-26
Community-Based Exercise Oncology: Real-World Evidence of High Adherence, Improved Quality of Life and Cost-Effectiveness Across the Cancer Continuum
University of Castilla-La Mancha
Active not recruiting
NCT04208347 2026-01-23
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2/3 Active not recruiting
NCT05283577 2026-01-23
EAST
University of California, Irvine
Phase NA Active not recruiting
NCT05455606 2026-01-22
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
SWOG Cancer Research Network
Phase NA Active not recruiting
NCT03148418 2026-01-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting